Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sulfasalazine

FDA-approved product (tablet, oral), marketed as Azulfidine, Azulfidine En-Tabs, S.a.s.-500 and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sulfasalazine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Juvenile idiopathic arthritis
  • Rheumatoid arthritis
  • Ulcerative colitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Aminosalicylic acid and similar agents
FDA pharmacologic class
Aminosalicylate FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA32.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli20.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sulfasalazine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sulfasalazine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects

    NCT04720183 · start 2021-01-11

    Registered record
    Registry ID
    NCT04720183
    Conditions
    Healthy
    Interventions
    Sulfasalazine; GLPG3970
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-01-11
    Completion
    2021-04-23
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionSulfasalazine; GLPG3970
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)

    NCT03660059 · start 2018-09-27

    Registered record
    Registry ID
    NCT03660059
    Conditions
    Rheumatoid Arthritis (RA)
    Interventions
    Peficitinib; Plaebo; Disease-modifying antirheumatic drugs (DMARDs)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-09-27
    Completion
    2021-11-02
    Enrolment
    385

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis (RA)
    InterventionPeficitinib; Plaebo; Disease-modifying antirheumatic drugs (DMARDs)
    PhasePhase 3
    Registry statusCompleted

  • Optimal MTX Dose With Folic Acid Randomized Case-control Trial

    NCT04066803 · start 2018-08-01

    Registered record
    Registry ID
    NCT04066803
    Conditions
    Rheumatoid Arthritis
    Interventions
    MTX; Folic Acid; DMARDs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-08-01
    Completion
    2020-07-30
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionMTX; Folic Acid; DMARDs
    PhasePhase 4
    Registry statusUnknown

  • Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

    NCT03561584 · start 2018-07-01

    Registered record
    Registry ID
    NCT03561584
    Conditions
    Primary Sclerosing Cholangitis
    Interventions
    Sulfasalazine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-07-01
    Completion
    2026-03-03
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Sclerosing Cholangitis
    InterventionSulfasalazine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin

    NCT03801733 · start 2018-06-17

    Registered record
    Registry ID
    NCT03801733
    Conditions
    Drug Interaction Potentiation
    Interventions
    Vadadustat; Simvastatin; Rosuvastatin; Atorvastatin; Pravastatin; Sulfasalazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-06-17
    Completion
    2018-11-24
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interaction Potentiation
    InterventionVadadustat; Simvastatin; Rosuvastatin; Atorvastatin +2 more
    PhasePhase 1
    Registry statusCompleted

  • Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis

    NCT03531073 · start 2018-04-18

    Registered record
    Registry ID
    NCT03531073
    Conditions
    Psoriatic Arthritis
    Interventions
    Methotrexate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-04-18
    Completion
    2024-12-31
    Enrolment
    446

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriatic Arthritis
    InterventionMethotrexate
    PhaseNot recorded
    Registry statusCompleted

  • Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis

    NCT03449758 · start 2018-03-05

    Registered record
    Registry ID
    NCT03449758
    Conditions
    Rheumatoid Arthritis
    Interventions
    SARILUMAB; Azathioprine; Chloroquine; Hydroxychloroquine; Leflunomide; Methotrexate; Sulfasalazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-03-05
    Completion
    2019-07-31
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionSARILUMAB; Azathioprine; Chloroquine; Hydroxychloroquine +3 more
    PhasePhase 4
    Registry statusCompleted

  • Sequential Application of Yisaipu® and DMARDs in Treating Mild-to-Moderate AS

    NCT03411798 · start 2017-12-15

    Registered record
    Registry ID
    NCT03411798
    Conditions
    Ankylosing Spondylitis
    Interventions
    Yisaipu®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-12-15
    Completion
    2019-07-01
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnkylosing Spondylitis
    InterventionYisaipu®
    PhasePhase 4
    Registry statusCompleted

  • Comparative Efficacy and Safety of Thalidomide and Sulfasalazine in Moderate to Severe Ankylosing Spondylitis: A Real-World Study From Bangladesh

    NCT06985134 · start 2017-01-01

    Registered record
    Registry ID
    NCT06985134
    Conditions
    Comparative Efficacy and Safety of Thalidomide and Sulfasalazine in Moderate to Severe Ankylosing Spondylitis: A Real-World Study From Bangladesh; Condition ...Moderate to Severe Axial Spondyloarthopathy
    Interventions
    Comparative Efficacy and Safety of Thalidomide and Sulfasalazine in Moderate to Severe Ankylosing Spondylitis: A Real-World Study from Bangladesh
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-01-01
    Completion
    2018-12-31
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComparative Efficacy and Safety of Thalidomide and Sulfasalazine in Moderate to Severe Ankylosing Spondylitis: A Real-World Study From Bangladesh; Condition ...Moderate to Severe Axial Spondyloarthopathy
    InterventionComparative Efficacy and Safety of Thalidomide and Sulfasalazine in Moderate to Severe Ankylosing Spondylitis: A Real-World Study from Bangladesh
    PhasePhase 3
    Registry statusCompleted

  • Oral Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan Using Different Administration Mediums

    NCT03012763 · start 2016-04

    Registered record
    Registry ID
    NCT03012763
    Conditions
    Pharmacokinetics; Magnetic Resonance Imaging; Administration, Oral
    Interventions
    Paracetamol; Sulfasalazine; Fexofenadine; Valsartan; non-caloric water; caloric drink; grapefruit juice
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-04
    Completion
    Not recorded
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics; Magnetic Resonance Imaging; Administration, Oral
    InterventionParacetamol; Sulfasalazine; Fexofenadine; Valsartan +3 more
    PhasePhase 1
    Registry statusCompleted

  • Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide

    NCT02714634 · start 2016-03-30

    Registered record
    Registry ID
    NCT02714634
    Conditions
    Rheumatoid Arthritis; Insufficient Response to Methotrexate or Leflunomide
    Interventions
    Methotrexate + targeted therapy administration; methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2016-03-30
    Completion
    2029-03
    Enrolment
    286

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis; Insufficient Response to Methotrexate or Leflunomide
    InterventionMethotrexate + targeted therapy administration; methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration
    PhasePhase 4
    Registry statusRecruiting

  • Combination Therapy Prevents the Relapse of RA

    NCT02320630 · start 2015-10

    Registered record
    Registry ID
    NCT02320630
    Conditions
    Recurrence (Disease Attribute)
    Interventions
    Entanercept; HCQ; MTX
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2015-10
    Completion
    2020-09
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrence (Disease Attribute)
    InterventionEntanercept; HCQ; MTX
    PhaseNot applicable
    Registry statusUnknown

  • An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects

    NCT02434861 · start 2015-05

    Registered record
    Registry ID
    NCT02434861
    Conditions
    Chemotherapy-induced Nausea and Vomiting
    Interventions
    Rolapitant; Digoxin; Sulfasalazine; Cooperstown Cocktail
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-05
    Completion
    2015-08
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-induced Nausea and Vomiting
    InterventionRolapitant; Digoxin; Sulfasalazine; Cooperstown Cocktail
    PhasePhase 1
    Registry statusCompleted

  • Biomarkers of Remission in Rheumatoid Arthritis (BioRRA)

    NCT02219347 · start 2014-08

    Registered record
    Registry ID
    NCT02219347
    Conditions
    Rheumatoid Arthritis
    Interventions
    DMARD cessation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-08
    Completion
    2017-08
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionDMARD cessation
    PhaseNot applicable
    Registry statusCompleted

  • RICE: Remission by Intra-articular Injection Plus CErtolizumab

    NCT02293590 · start 2013-11

    Registered record
    Registry ID
    NCT02293590
    Conditions
    Rheumatoid Arthritis
    Interventions
    Certolizumab Pegol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-11
    Completion
    2018-01-15
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionCertolizumab Pegol
    PhasePhase 2
    Registry statusCompleted